Fig. 2From: Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5LFrequency (%) of problems on FACT-8D and EQ-5D-5L dimensions at baseline, by baseline ECOG status. FACT-8D. EQ-5D-5L. Note: n = 31 (26.5%) ECOG0 patients had no problems on any EQ-5D dimension at baseline compared to n = 9 (6.9%) of ECOG1 patientsBack to article page